Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 4/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779492 | 0.91 | ROCK2 (0.46) | ROCK2NOTUMPRMT3IMPDH2 | |
| SCHEMBL16040568 | 0.90 | ROCK2 (0.49) | ROCK2ROCK1NOTUMPRMT3IMPDH2 | |
| SCHEMBL15844207 | 0.87 | NOTUM (0.42) | ROCK2ROCK1NOTUMPRMT3IMPDH2 | |
| SCHEMBL115009 | 0.86 | ROCK2 (0.53) | ROCK2ROCK1MYLK4NOTUMPRMT3 | |
| SCHEMBL1094669 | 0.85 | NOTUM (0.44) | ROCK2NOTUMPRMT3IMPDH2 | |
| SCHEMBL15844181 | 0.83 | NOTUM (0.47) | ROCK2ROCK1NOTUMPRMT3IMPDH2 | |
| SCHEMBL2778219 | 0.83 | NOTUM (0.42) | ROCK2ROCK1MYLK4NOTUMPRMT3 | |
| SCHEMBL2777629 | 0.82 | NOTUM (0.44) | ROCK2ROCK1NOTUMIMPDH2 | |
| SCHEMBL13404759 | 0.80 | NOTUM (0.53) | ROCK2ROCK1NOTUMPRMT3IMPDH2 | |
| SCHEMBL113278 | 0.78 | NOTUM (0.49) | ROCK2ROCK1NOTUMPRMT3IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001848-A1 | ROCK INHIBITORS AND USES THEREOF | ALCON INC (CH) | 2026-01-01 | — | — | US | disclosed |
| EP-4335507-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4218759-A2 | COMBINATION THERAPY | Aerie Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3811943-B1 | COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220088000-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2022-03-24 | — | — | US | disclosed |
| US-11197853-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11185538-B2 | Compositions for treating glaucoma or reducing intraocular pressure | AERIE PHARMACEUTICALS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| CN-109528721-B | Combination therapy | 爱瑞制药公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2014144781-A1 | COMBINATION THERAPY | AERIE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275160-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275161-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8716310-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20220088000-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
| US-11185538-B2 | Compositions for treating glaucoma or reducing intraocular pressure | PTGS1, PTGIS, PTGS2 | ROCK2 55/4885ROCK1 52/4885MYLK4 383/4885 |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20140275160-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-11197853-B2 | Combination therapy | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | ROCK2 2/4885ROCK1 6/4885MYLK4 196/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MYLK4 146/4885 |
| US-20140275161-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885MYLK4 594/4885 |
| US-20260001848-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, PRKG1 | ROCK2 2/4885ROCK1 1/4885MYLK4 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.